In another study, treatment of patients with decompensated cirrhosis with G-CSF and erythropoietin for 1 month reduced liver disease severity (CTP score) and improved survival at 12 months follow-up compared to placebo, and significantly fewer patients in the treatment arm developed sepsis during follow up (n = 26–29 per group) (119). This evidence concerns the gene CSF3 and Cirrhosis.